Paul M. Lieberman, Ph.D., the Hilary Koprowski, M.D., Endowed Professor, leader of the Gene Expression and Regulation Program, and director of the Center for Chemical Biology & Translational Medicine at The Wistar Institute, a biomedical research leader in cancer, immunology, infectious disease, and vaccine development, has joined the NDRI Board of Directors. Elected on November 12 to a three-year term, Lieberman will bring his experience and insight to the nation’s leading source of human organs, cells, and tissues for research.
Lieberman is a molecular virologist and an expert in gene expression and regulation at Wistar’s Cancer Center. He is best known for his pioneering studies on how certain viruses can persist in the body long-term, leading to cancer. He leads a talented drug-discovery team that created first-in-class molecules directed against Epstein-Barr virus (EBV) as a novel therapeutic approach for potentially treating EBV-associated cancers.
Lieberman earned a B.A. in Chemistry from Cornell University and a Ph.D. in pharmacology/virology from the Johns Hopkins University School of Medicine. He completed post-doctoral training at the University of California in Los Angeles. Lieberman’s research has been cited in over 150 publications. In 2018, Lieberman was named a 2018 Fellow of the Association of American Advancement of Sciences (AAAS).
Mary J.C. Hendrix, Ph.D., Chair of the NDRI Board and President of Shepherd University, shared; “We are thrilled to welcome Dr. Lieberman to the NDRI Board of Directors. His scientific expertise and accomplishments and strong commitment to the advancement of research will serve as great contributions to NDRI’s mission.”
